Finance
Reckitt misses first-quarter sales estimates, shares slide
Published by Global Banking & Finance Review®
Posted on April 23, 2025
2 min readLast updated: January 24, 2026
Global Banking & Finance Review®
Company
Published by Global Banking & Finance Review®
Posted on April 23, 2025
2 min readLast updated: January 24, 2026
Reckitt's first-quarter sales fell short, causing a share drop. European and North American markets saw declines amid economic challenges.
By Richa Naidu
LONDON (Reuters) -Reckitt, the maker of Dettol and Lysol cleaning products, on Wednesday missed first-quarter like-for-like net sales growth estimates as volumes in its top European and North American markets fell, sending its shares down.
The company maintained its full-year expectations of like-for-like net sales growth of 2%-4%, though it noted "the more challenging macroeconomic outlook."
A global trade war sparked by U.S. President Donald Trump has prompted economic uncertainty and fears of a recession. Consumer staples companies are considered more resilient during economic downturns, but big brands like Reckitt, P&G and Unilever increasingly face stiffer competition from cheaper private label brands that gained popularity during the COVID-19 pandemic.
"Given that Reckitt is in the middle of a complex turnaround, we view no news as good news in terms of operational performance," Barclays analyst Iain Simpson said. "We note widespread apprehension around this results season across consumer staples given the limited macro outlook."
Reckitt shares were down by more than 4.5% in morning trade.
The company's first-quarter like-for-like net sales rose 1.1%, below the 1.4% analysts had expected in a company-supplied poll. Sales volumes declined in Europe and North America, two of Reckitt's biggest markets, by 4.7% and 1.8%, respectively.
Price/mix, a metric that reflects how much Reckitt sold its products for, rose 3%, and volumes declined 1.9% overall on a group level. Analysts expected price/mix to rise by 1.3% and volumes to be flat.
The company, whose other products include Nurofen tablets, cold remedy Lemsip and Durex condoms, said it was "closely monitoring the evolving situation around global tariffs and the potential impacts on our supply chain and cost base."
Some investors have said they worry Reckitt is more exposed than its rivals in the United States due to its lower manufacturing capacity there compared to companies such as Haleon and Unilever.
Reckitt said on Wednesday that tariffs would have an "immaterial annualised impact on its cost of goods sold base" that it could mitigate.
(Reporting by Richa Naidu Editing by Jane Merriman and Tomasz Janowski)
The article discusses Reckitt's first-quarter sales performance and the resulting decline in share prices.
Reckitt's shares dropped due to missed sales estimates and declining volumes in key markets.
Reckitt faces competition from private labels and economic uncertainty due to global trade issues.
Explore more articles in the Finance category
